About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« The Red Queen's Race For Funding | Main | Touching Up the Spectra »

July 15, 2013

Does That Answer Your Question? Not Quite, No.

Email This Entry

Posted by Derek

John Carroll at Fierce Biotech contacted the NIH, wanting to know more about a newspaper report that the NIH had terminated dozens of clinical trials in India as new regulations come in. What sort of answer did he get? Authentic frontier gibberish, for sure, the sort of thing you'd expect from a UN press release, a State Department briefing, or other such sources of natural gas. He's trying to pressure Francis Collins and the agency to come up with something substantial, which would be most anything compared to what he's gotten so far, and I'm glad to help out in any way I can.

Comments (8) + TrackBacks (0) | Category: Clinical Trials


1. Anon on July 15, 2013 1:44 PM writes...

Looks like someone is going to have to use the old Freedom on Information Request.
Ever since Collins refused to recognize his own committee's report on the overproduction of PhDs I haven't had much respect for his actions.

Permalink to Comment

2. s on July 15, 2013 3:50 PM writes...

Francis Collins [...] to come up with something substantial
Can I have a pony, while we're at it? Permalink to Comment

3. Anonymous on July 15, 2013 4:32 PM writes...

How does a gin and tonic slide off a rhino skin ? Is there something odd about the hydrophobicity of rhino skin or will any old pachyderm do for this analogy ?

Permalink to Comment

4. drug_hunter on July 15, 2013 5:03 PM writes...

I think Balzac is more in vogue at Princeton these days

Permalink to Comment

5. ROGI on July 15, 2013 5:06 PM writes...

If you read down to the last paragraph of "The Mint" article, you see the following appalling statistics..."According to documents submitted by the Drugs Controller General of India in the Supreme Court, between January 2005 and June 2012, India approved 475 clinical trials for “new chemical entities” not used as drugs elsewhere in the world. The documents said that 11,972 adverse effects, excluding deaths, were reported in the period, with 506 of these being directly attributable to the trials. They put deaths from trials at 2,644 over the last five years."

I shiver just reading this. And for any western pharmaceutical or clinical entity to even
entertain conducting studies in a country with such a cavalier view on life defies my imagination.

Permalink to Comment

6. luysii on July 15, 2013 7:01 PM writes...

#4 -- What does Princeton have to do with any of this?

Permalink to Comment

7. Dr. Manhattan on July 15, 2013 8:11 PM writes...

"I am particularly glad that these lovely children are here today to hear that speech. Not only was it authentic frontier gibberish, it expressed the courage little seen in this day and age."

As to possible answers to John Carroll's queries, Dr. Collins said, "My mind is a raging torrent, flooded with rivulets of thought cascading into a waterfall of creative alternatives."

I love Mel Brooks' references...

Permalink to Comment

8. drug_hunter on July 16, 2013 9:53 PM writes...

#6 luysii - A reference to a line from John Carroll's original piece about the literature upon which old tigers were weaned...

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry